We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01505634
Recruitment Status : Completed
First Posted : January 6, 2012
Last Update Posted : August 14, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.